These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28243182)

  • 21. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
    Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
    BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data.
    Bovis F; Carmisciano L; Signori A; Pardini M; Steinerman JR; Li T; Tansy AP; Sormani MP
    BMC Med; 2019 Jun; 17(1):113. PubMed ID: 31208412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
    Spiegelstein O; Mimrod D; Rabinovich L; Eyal E; Sprenger C; Elgart A; Samara E; Morganroth J
    Clin Pharmacol Drug Dev; 2019 Jan; 8(1):49-59. PubMed ID: 29786964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
    Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
    Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of laquinimod in multiple sclerosis: current status.
    Haggiag S; Ruggieri S; Gasperini C
    Ther Adv Neurol Disord; 2013 Nov; 6(6):343-52. PubMed ID: 24228070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
    Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
    Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Laquinimod in the treatment of relapsing remitting multiple sclerosis.
    Hainke U; Thomas K; Ziemssen T
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):701-9. PubMed ID: 27089834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.
    Kohler S; Zeller C; Iliev H; Kaspers S
    Adv Ther; 2017 Jul; 34(7):1707-1726. PubMed ID: 28631216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
    Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
    Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
    Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
    Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular safety of hydroxypropyl-β-cyclodextrin-diclofenac in the management of acute postsurgical pain: a pooled analysis of 2 randomized, double-blind, placebo- and active comparator-controlled phase III clinical trials.
    Gan TJ; Singla N; Daniels SE; Lacouture PG; Min LH; Reyes CR; Carr DB
    J Clin Anesth; 2016 Jun; 31():249-58. PubMed ID: 27185721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma.
    Scott MB; Skoner DP
    J Allergy Clin Immunol; 1999 Oct; 104(4 Pt 2):200-9. PubMed ID: 10518847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.
    Toth PP; Descamps O; Genest J; Sattar N; Preiss D; Dent R; Djedjos C; Wu Y; Geller M; Uhart M; Somaratne R; Wasserman SM;
    Circulation; 2017 May; 135(19):1819-1831. PubMed ID: 28249876
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.